Phase 2
Completed N=7
Lipoic Acid to Treat Chronic Inflammatory Demyelinating Polyneuropathy
Source: ClinicalTrials.gov NCT00962429 ↗Enrolled (actual)
7
Serious AEs
—
Results posted
Aug 2020
Primary outcomePrimary: Muscle Strength
Summary
The purpose of the study is to examine if alpha lipoic acid is an effective treatment for chronic inflammatory demyelinating polyneuropathy (CIDP).
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Muscle Strength |
— | — |
| SECONDARY Hughes Functional Disability Scale |
— | — |
| SECONDARY Forced Vital Capacity (FVC) |
— | — |
| SECONDARY Motor Nerve Conduction Studies (NCS) |
— | — |
Eligibility Criteria
Inclusion Criteria
- diagnosis of CIDP
- on a stable dose of immunotherapy for at least 3 months before enrolling in the study
Exclusion Criteria
- myelopathy or evidence of central demyelination
- persistent neurological deficits from stroke, CNS trauma, or peripheral neuropathy from other causes (eg, diabetes mellitus, IgM, paraproteinaemia, or uraemic, toxic, or familial neuropathy)
- evidence of systemic disease that might cause neuropathy
- heart diseases (congestive heart failure or arrhythmia)
- pulmonary conditions (asthma or CIPD)
- rheumatoid conditions (such as rheumatoid arthritis)
- renal failure
Data sourced from ClinicalTrials.gov (NCT00962429). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.